Philips has announced the launch of the RADIQAL clinical trial, a randomized, multicenter study involving 824 patients with coronary artery disease.

The trial, conducted in six hospitals in Spain, the Czech Republic, and the United States, aims to evaluate whether its new ultra-low-dose X-ray technology can reduce radiation exposure by 50% without compromising image quality or procedural performance.

The first patient was enrolled at Aarhus University Hospital in Denmark, Philips said.


Copyright (c) 2025 CercleFinance.com. All rights reserved.